NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Hims & Hers Health
HIMS
US Stock MarketDetailed Quotes
PSNL Personalis
- 4.230
- -0.345-7.54%
Close Feb 25 16:00 ET
358.25MMarket Cap-2.45P/E (TTM)
4.550High4.020Low1.70MVolume4.500Open4.575Pre Close7.17MTurnover3.81%Turnover RatioLossP/E (Static)84.69MShares7.20052wk High2.15P/B189.14MFloat Cap1.13552wk Low--Dividend TTM44.71MShs Float53.460Historical High--Div YieldTTM11.59%Amplitude0.891Historical Low4.211Avg Price1Lot Size
Personalis Stock Forum
has options
$Personalis (PSNL.US)$
nfa
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
Thursday, 19th December at 9:00 am
Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company's business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Mode...
Personalis and Tempus Expand Collaboration to Biopharma
Monday, 16th December at 8:00 am
Expanded collaboration to yield greater biopharma access to Personalis' MRD solution
Personalis, Inc. (NASDAQ: PSNL) and Tempus AI, Inc. (NASDAQ: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Soc...
No comment yet